Fortive Corporation (FTV) Stock Price & How to Invest

Fortive Corporation is a technology solutions company that was itself spun out of Danaher in 2016 and has since used the Danaher-style operating playbook to build recurring-revenue businesses. In June 2025 it completed the spin-off of its Precision Technologies segment as Ralliant (RAL), which took brands like Tektronix and specialty sensors with it, leaving Fortive with two segments. Intelligent Operating Solutions (IOS) is anchored by the Fluke test-and-measurement brand plus facilities and asset-management software (Accruent, Gordian, ServiceChannel). Advanced Healthcare Solutions (AHS) covers hospital sterilization and infection prevention (ASP) and clinical workflow software (Provation, Censis).

The investment picture centers on quality and recurring revenue: roughly half of sales are recurring, adjusted EBITDA margins sit near 29 percent, and the company generates strong free cash flow (about $940 million over the last twelve months) that funds buybacks and bolt-on acquisitions. Q1 2026 showed revenue around $1.07 billion (up ~7.7 percent) and about 25 percent adjusted EPS growth, and Q2 2026 followed with revenue of about $1.10 billion (up ~7.9 percent) and adjusted EPS of $0.74 against a $0.71 estimate. Trailing revenue is now about $4.3 billion. The shares closed at $57.78 on October 16, 2026, up 4.3% year to date and 18.7% over one year, though off about 5% over three months as RBC, JPMorgan and Truist cut price targets in early October. Q3 results are due October 28, with consensus near $0.71 of adjusted EPS on about $1.07 billion of revenue. The trade-off is valuation: FTV still trades at a premium trailing multiple, so returns depend on continued margin expansion, capital deployment, and durable end-market demand rather than a cheap entry point.

Fortive trades at a premium trailing valuation (about 30x earnings as of October 2026), so any growth disappointment or multiple compression could pressure the stock; consensus expects Q4 2026 revenue growth to dip slightly negative, and analysts at RBC, JPMorgan and Truist cut targets in October. Its industrial end markets are cyclical and exposed to manufacturing, construction and facilities spending, which can soften in a downturn. The healthcare segment faces hospital capital-spending cycles and competitive infection-prevention alternatives. Serial acquisitions carry integration and goodwill-impairment risk, and the recent spin-off adds comparability noise to reported results. Currency and global supply-chain costs can also swing margins quarter to quarter.

14 analysts publish price targets on FTV, averaging $62.79 against a $57.79 price as of October 2026, or +8.7%. The published targets run from $51.00 to $72.00, a moderate spread, and the ratings split 4 buy, 10 hold, 2 sell. Over the last six months there have been 6 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full FTV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Fortive Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Recurring revenue and software mix. Roughly half of Fortive's revenue is recurring, spread across software (Accruent, Gordian, ServiceChannel, Provation) and consumables (ASP sterilization). The most optimistic published target, $72.00, assumes this works close to its best case.

The case against. Fortive trades at a premium trailing valuation (about 30x earnings as of October 2026), so any growth disappointment or multiple compression could pressure the stock; consensus expects Q4 2026 revenue growth to dip slightly negative, and analysts at RBC, JPMorgan and Truist cut targets in October. The most pessimistic target, $51.00, is roughly what FTV is worth if this bites instead.

Read the full bull and bear case on FTV, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Fortive Corporation (FTV) has had 2 share splits in the last 10 years:

• 1195:1000 on October 9, 2020, so every share held became 1.195 shares.
• 1327:1000 on June 30, 2025, so every share held became 1.327 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of FTV the day before the 1327:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Fortive Corporation's investor relations page or your broker.

• Revenue (TTM, post-spin): ~$4.3B
• Q2 2026 revenue: ~$1.10B (up ~7.9% YoY)
• Adjusted EPS (Q2 2026): $0.74 vs $0.71 est.
• Margins (TTM): ~63% gross, ~19% operating, ~12% net
• Market cap: ~$17.6B (share price ~$57.78)
• P/E: ~30x trailing, ~18x forward
• Dividend yield: ~0.5% ($0.28 a year)

After the Ralliant spin-off, Fortive's continuing-operations revenue base is about $4.3 billion, smaller than the pre-spin company but higher-margin. The trailing P/E near 30x is inflated by amortization and spin-related costs in GAAP earnings; on adjusted forward EPS the multiple is about 18x and EV/EBITDA about 16.8x. The average target from 14 analysts is about $63 (consensus rating hold), and Q3 2026 results on October 28 carry a consensus of roughly $0.71 of adjusted EPS.

Other names that sit close to FTV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get FTV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so FTV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where FTV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

FTV is a focused, high-margin industrial-tech and healthcare-software operator whose appeal rests on recurring revenue and steady core growth, weighed against a valuation of about 30x trailing (18x forward) earnings. It has beaten EPS estimates four quarters running, but several analysts trimmed price targets in October 2026 ahead of Q3 results on October 28.

Whether FTV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is FTV a buy or a sell?, and where the stock could go from here in the FTV stock forecast.

For income investors, whether FTV pays a dividend and how the payout looks is covered in does FTV pay a dividend? And to weigh FTV against a peer, read the full side-by-side comparisons: FTV vs RAL and FTV vs IBM.